Monthly Archives: March 2008

Better Late than Never? FDA Oks Slower Approvals

As mentioned in yesterday’s post, the FDA has signaled that due to work burden, the agency will be allowing PDUFA dates to be missed… The RPM Report got the lowdown from John Jenkins, director of the Office of New Drugs … Continue reading

Posted in FDA Policy | Comments Off on Better Late than Never? FDA Oks Slower Approvals

Turning Down the Pipeline on Biotechnology

On the Ides of March, Genetic Engineering and Biotechnology News (GEN) published an article by Ronald A. Rader, President of the Biotechnology Information Institute that provided an overview of the product approval rate focusing solely on biologics.  For a long … Continue reading

Posted in Biologics | 2 Comments

Approvable Letter for MRSA Treatment

Basilea Pharmaceutica announced today that the FDA has issued an approvable letter for its first-in-class anti-MRSA agent cephalosporin for which company sought an indication to treat skin infections and diabetic foot infections. According to the company, prior to approval the … Continue reading

Posted in Approvable Letters | Comments Off on Approvable Letter for MRSA Treatment

Putting FDA Under the Congressional Microscope

Last week, the FDA offered testimony before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations regarding food safety delivered by Stephen F. Sundlof, DVM, PhD,  Director at the Center for Food Safety and Applied Nutrition.  It … Continue reading

Posted in Current Affairs | Comments Off on Putting FDA Under the Congressional Microscope

American Health & Drug Benefits

I’ve been writing a column called FDA Watch for a new peer reviewed journal called American Health & Drug Benefits.  The maiden issue came out in February and included an article by Newt Gingrich and Nancy Desmond called "Creating a … Continue reading

Posted in Useful Resources | 1 Comment